By Stephen Gacheru, Ph.D., Vice President, Analytical Development and Technical Operations at Center for Breakthrough Medicines

Published in: Cell and Gene Newsletter

Published on: October 13, 2021

Given the rapid emergence of gene therapies based on recombinant adeno-associated virus (rAAV), there is a great need for appropriate analytical tools to support every lifecycle stage of these products.

Advance Stability Knowledge

Would you like to see a particular publication, guidance, organization, supplier, event, or career opportunity on StabilityHub? Contact us with your suggestion!